PDF) Four-Year Maintenance Treatment With Adalimumab in Patients with Moderately to Severely Active Ulcerative Colitis: Data from ULTRA 1, 2, and 3
Ulcerative Colitis Clinical Trials - GEMINI I Study | Entyvio®
Biologics in the management of ulcerative colitis – comparative | TCRM
Biologics in the management of ulcerative colitis – comparative | TCRM
VARSITY Ulcerative Colitis Clinical Trial | Entyvio® (vedolizumab)
Efficacy and Safety of Continued Treatment With Mirikizumab in a Phase 2 Trial of Patients With Ulcerative Colitis - Clinical Gastroenterology and Hepatology
Adalimumab may be efficacious, safe treatment for children with ulcerative colitis
Crohn's Remission and Results With HUMIRA® (adalimumab)
Comparative efficacy of antitumor necrosis factor agents and tacrolimus in naïve steroid-refractory ulcerative colitis patients | Scientific Reports
Safety | Crohn's Disease (CD) | HUMIRA® (adalimumab)
Ulcerative Colitis Remission & HUMIRA® Results (adalimumab)
HUMIRA (adalimumab) for the Treatment of Ulcerative Colitis
VARSITY Ulcerative Colitis Clinical Trial | Entyvio® (vedolizumab)
Long-Term Safety of Adalimumab (HUMIRA) in Adult Patients from Global Clinical Trials across Multiple Indications: An Updated Analysis in 29,987 Patients Representing 56,951 Patient-Years - ACR Meeting Abstracts
HUMIRA® (adalimumab) for adults with Ulcerative Colitis (UC)
HUMIRA (adalimumab) Citrate-Free | Official HCP Site
Efficacy | Ulcerative Colitis (UC) | HUMIRA® (adalimumab)
Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative Colitis - Gastroenterology
UC Patients on Humira Show Improvements in Early Disease Features
Efficacy and safety of adalimumab in paediatric patients with moderate-to-severe ulcerative colitis (ENVISION I): a randomised, controlled, phase 3 study - The Lancet Gastroenterology & Hepatology
Vedolizumab versus Adalimumab for Ulcerative Colitis (part 2) | gutsandgrowth
Ulcerative Colitis: Today, Tomorrow, and the Future - European Medical Journal
Real‐world evidence on adherence, persistence, switching and dose escalation with biologics in adult inflammatory bowel disease in the United States: A systematic review - Khan - 2019 - Journal of Clinical Pharmacy
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease | NEJM
Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis | NEJM
Histologic Outcomes With Vedolizumab Versus Adalimumab in Ulcerative Colitis: Results From An Efficacy and Safety Study of Vedolizumab Intravenous Compared to Adalimumab Subcutaneous in Participants With Ulcerative Colitis (VARSITY) - Gastroenterology
